Navigation Links
FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Date:3/17/2008

FDA Clearance Validates Platform Designed to Deliver Electronic X-ray-Based Therapy Directly to Cancer Sites in Minimally Shielded Clinical Settings

SUNNYVALE, Calif., March 17 /PRNewswire/ -- Xoft, Inc., today announced that it has received expanded clearance from the U.S. Food & Drug Administration (FDA) for the Axxent(R) Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated.

As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.

"The prospect of expanding the use of Electronic Brachytherapy beyond our breast cancer patients is very exciting," said Adam Dickler, radiation oncologist at Little Company of Mary Hospital in Chicago. "The ability to deliver electronic X-ray based therapy directly to the cancer site spares healthy tissue and gives us the ability to provide that therapy in a broader spectrum of clinical settings. This tool has been very well received by our breast cancer patients and we would expect it deliver similar benefits across a range of cancer treatments."

Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in virtually any clinical setting under the supervision of a radiation oncologist. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.

In its current use for the treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

"The expanded clearance for the Axxent Controller is very significant in that it validates that the FDA recognizes Electronic Brachytherapy is a platform technology that is viable for treatment of conditions outside of the breast," said Michael Klein, president and CEO of Xoft. "This serves as the foundation for Xoft's expansion into new treatment areas beyond breast cancer and fuels the continued market adoption and expansion of this important technology."

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New filter clears up fiber optic communications
2. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
8. HOYA ConBio and The Hornbrook Group Announce Expanded Alliance
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
11. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in ... molecular test results from tumors with previously documented positive, negative, and equivocal ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that ... and will take place on February 1-3, 2017 at the Roosevelt Hotel in New ... the program provides a unique 360-degree approach, which addresses the most up-to-date information regarding ...
(Date:12/2/2016)... ... December 02, 2016 , ... The ... to collaboratively developing improved chemistry, manufacturing and control technologies for the pharmaceutical ... with robust, probe-based sampling. , Online liquid chromatography analysis is becoming ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):